Tenecteplase

證據等級: L5

預測適應症: 10 個

Tenecteplase: From STEMI Thrombolysis to Adjunctive Intracoronary Use in Coronary Stenosis

One-Sentence Summary

Tenecteplase is a third-generation recombinant tissue plasminogen activator, established as a standard IV thrombolytic for ST-elevation myocardial infarction (STEMI). Among ten TxGNN-predicted indications, most (ranks 1–3, 6–10) are either anatomical ECG subtypes of STEMI already within its known mechanism, or disease-embedding false positives with no biological plausibility. The one candidate with real supporting evidence is Coronary Stenosis — low-dose intracoronary tenecteplase as an adjunct during primary PCI — backed by 1 completed Phase 2 RCT and 12 supporting publications.

Quick Overview

Item	Content
Original Indication	STEMI thrombolysis (per repurposing rationale text; no official label text available — drug not marketed in Germany)
Predicted New Indication	Coronary Stenosis (adjunctive low-dose intracoronary use during primary PCI)
TxGNN Prediction Score	99.53%
Evidence Level	L2
Germany Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (data gap, high severity). Based on the information present in this evidence pack, tenecteplase is a fibrin-specific tPA variant that activates plasminogen→plasmin to dissolve thrombus; it is already the standard thrombolytic for STEMI. In this context, "coronary stenosis" is not a wholly separate disease but a description of the culprit lesion treated during primary PCI — low-dose intracoronary (rather than systemic IV) tenecteplase given at the time of balloon angioplasty is hypothesized to dissolve residual thrombus at the lesion site and improve microvascular perfusion, reducing distal embolization.

It is worth noting that TxGNN ranked three other candidates higher by raw score — posterolateral, posteroinferior, and septal myocardial infarction (ranks 1–3). These are not independent diseases but ECG-based anatomical classifications of STEMI itself, so they fall squarely within tenecteplase's already-established indication rather than representing genuine repurposing. None of the three has direct supporting clinical trials, and only septal MI has tangential literature (a misdiagnosed PE case and a general PE-efficacy study). Ranks 6–10 (chromosomal deletion syndromes, thalassemia, red-cell enzyme deficiencies, hereditary pyropoikilocytosis) have no known link to the fibrinolytic pathway and are best treated as knowledge-graph embedding noise. Coronary stenosis (rank 5) is therefore the only candidate with real actionable evidence, and this report focuses on it.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00604695	Phase 2	Completed	40	ICE-T trial: evaluated low-dose intracoronary tenecteplase as an adjunct during balloon angioplasty for STEMI; hypothesis that IC tenecteplase enhances clot breakdown at the culprit lesion, reducing myocardial damage.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
17102829	2006	RCT	Canadian Journal of Cardiology	TRANSFER-AMI pilot: feasibility of urgent PCI transfer shortly after thrombolysis for STEMI.
16053952	2005	RCT	Journal of the American College of Cardiology	CAPITAL AMI study: tenecteplase-facilitated angioplasty vs. tenecteplase alone in high-risk STEMI.
31870492	2020	Cohort/Feasibility	American Journal of Cardiology	ICE-T-TIMI-49: feasibility and safety of low-dose IC tenecteplase (4 mg) vs. saline during primary PCI, randomized 40 patients.
16139127	2005	Cohort	Journal of the American College of Cardiology	Pre-procedural intracoronary fibrin-specific lytic infusion facilitates recanalization of chronic total occlusions.
37199147	2023	Cohort	Circulation	Shorter door-to-needle times associated with better outcomes after IV thrombolysis + endovascular thrombectomy in acute ischemic stroke.
11994554	2002	Cohort	Journal of Thrombosis and Thrombolysis	Precordial ST depression in inferior MI associated with slow flow in non-culprit LAD.
23615379	2013	Review	Cerebrovascular Diseases	Historical perspective and future opportunities for thrombolytics in acute ischaemic stroke.
37823944	2023	Case Report	Egyptian Heart Journal	Clopidogrel resistance leading to subacute stent thrombosis in a resource-limited setting.
25733729	2016	Case Report	Human & Experimental Toxicology	Thrombolytic therapy in inferolateral MI following carbon monoxide poisoning.
31020237	2019	Case Report	European Heart Journal Case Reports	Successful stent-retriever extraction of refractory thrombus from an ectatic coronary artery during primary angioplasty.

Germany Market Information

Tenecteplase currently has no marketing authorization on record in Germany (0 authorizations; market status: Not Marketed). No product-level licensing data is available for review.

Safety Considerations

Please refer to the package insert for safety information. No structured warnings, contraindications, or drug-drug interaction data are currently available in this evidence pack (key safety data and TFDA/BfArM label information are flagged as a Blocking data gap for the S1 safety review).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Coronary stenosis (adjunctive low-dose intracoronary tenecteplase during primary PCI) is the only candidate among the ten TxGNN predictions with actual clinical evidence — a completed Phase 2 RCT plus supportive cohort and RCT literature — reaching evidence level L2. However, this is an adjunctive procedural use with a narrow dose/route (low-dose intracoronary bolus) rather than a new systemic indication, and no head-to-head efficacy/outcome data exists yet for a formal "coronary stenosis" label.

To proceed, the following is needed:

Official label/warnings data (TFDA or BfArM) to complete the S1 safety review — currently blocking
Detailed mechanism of action documentation from DrugBank
Dose-response and bleeding-risk safety data specific to low-dose intracoronary administration
Drug-drug interaction data (currently not found)
Formal exclusion of ranks 1–3 (STEMI ECG subtypes — mechanistically non-novel, no direct evidence) and ranks 6–10 (no mechanistic plausibility, likely embedding noise) from further repurposing consideration
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.